Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | GHSR | Q92847 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2009168 | 0.99 | MLNR (0.98) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL3134464 | 0.92 | MLNR (0.85) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL2008839 | 0.92 | MLNR (0.85) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL4743902 | 0.91 | MLNR (0.84) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL2010875 | 0.91 | MLNR (0.84) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL2005788 | 0.88 | MLNR (0.78) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL2007976 | 0.85 | MLNR (1.00) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL2008090 | 0.84 | MLNR (0.73) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL2012437 | 0.81 | MLNR (1.00) | MLNRCYP3A4 | |
| SCHEMBL3134318 | 0.80 | MLNR (0.71) | MLNRCYP3A4CYP2D6GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | claimed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | claimed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | claimed |
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | MLNR 47/4885CYP3A4 1125/4885CYP2D6 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.